Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds ‘X4 Pharmaceuticals gets FDA Orphan Drug Designation for Mavorixafor for treatment of Waldenstrom’s Macroglobulinemia’ -TradeHawk, Citing FDA Site

FDA
News

‘X4 Pharmaceuticals gets FDA Orphan Drug Designation for Mavorixafor for treatment of Waldenstrom’s Macroglobulinemia’ -TradeHawk, Citing FDA Site

https://twitter.com/TradeHawk/status/1542897334085775360

byBill Haddad

July 1, 2022

1 minute read

$XFOR X4 Pharmaceuticals gets FDA Orphan Drug Designation for Mavorixafor for treatment of Waldenstrom's Macroglobulinemia https://t.co/jWDxETqrBy

— TradeHawk (@TradeHawk) July 1, 2022

Thomson Reuters Buys Casetext To Up The AI Game

By Lekha Gupta

June 27, 5:10 AM

Thomson Reuters Corp (NYSE: TRI) inked a deal to acquire Casetext for

MSFT

Deutsche Bank Maintains Buy on Oshkosh, Lowers Price Target to $85

By Benzinga Newsdesk

October 13, 9:18 AM

Deutsche Bank analyst Nicole Deblase maintains Oshkosh (NYSE:OSK) with a Buy and lowers the price target from $95 to $85.

OSK

Wana Brands Launches Portfolio Of Fast Acting Cannabis Gummies In Arizona

By Vuk Zdinjak

June 2, 10:30 AM

Arizonans can now access an expanded portfolio of Wana Brands’ cannabis-infused gummies, including Wana Quick Fast-Acting gummies in happy hour flavors and Wana Optimals Fast Asleep.

CGC